High Times
Home > Boards > US Listed > Biotechs >

Amgen (AMGN)

AMGN RSS Feed
Add AMGN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/16/2018 11:24:34 AM - Followers: 17 - Board type: Free - Posts Today: 0

This board is for fundamental and technical discussion about Amgen, AMGN. Amgen Inc. (Amgen) is a global biotechnology company. It discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of supportive cancer care, nephrology, inflammation and oncology. In September 2006, Vectibix (panitumumab), Amgen's first oncology therapeutic, received the United States Food and Drug Administration approval and became commercially available in October 2006. The Company's principal products include Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), NEUPOGEN (Filgrastim), EPOGEN (Epoetin alfa) and Enbrel (etanercept). On April 1, 2006, Amgen acquired Vectibix as part of its acquisition of Abgenix, Inc. On October 24, 2006, it acquired Avidia, Inc., which discovered and developed a class of human therapeutic known as Avimer proteins. In July 2007, it acquired Alantos and Ilypsa. Share Price: $40.11 3/20/2008 52 Week High: $69.11 52 Week Low: $39.16 EPS: $2.82 P/E Ratio: 14.22 Outstanding Shares: 1.09 Billion AMGEN INC 1 Amgen Center Dr Thousand Oaks, CA 91320-1799 USA Phone: 805-447-1000 Fax: 805-447-1010 http://www.amgen.com Daily One-Year Charts Weekly Five-Year Charts
High Times
AMGN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMGN News: Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies 10/18/2018 09:00:00 AM
AMGN News: Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe 10/16/2018 12:00:00 AM
AMGN News: FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapse... 10/01/2018 09:00:00 AM
AMGN News: BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia 09/24/2018 09:00:00 PM
AMGN News: S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion 09/24/2018 10:01:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#408   AMGN, NVS launch Humira biosimilars in Europe, pursuant DewDiligence 10/16/18 11:24:34 AM
#407   AMRN, AMGN mentioned here: north40000 09/24/18 01:41:11 PM
#406   AMGN 2Q18 CC slides: DewDiligence 07/26/18 04:58:00 PM
#405   $AMGN and 3 Drug and Biotech Stocks Awaiting MazelTov 07/13/18 10:10:13 AM
#404   AMGN completes $10B buyback via tender offer for DewDiligence 03/06/18 11:47:49 AM
#403   AMGN 4Q17 CC slides: DewDiligence 02/01/18 05:00:31 PM
#401   Head And Shoulder Pattern Formation On Amgen, Inc. ITMS 12/27/17 12:40:23 PM
#400   You are doing an excellent job...... following u winner06 11/20/17 10:02:43 PM
#399   This Biotech Stock Struggles To Hold Key Level ITMS 11/20/17 12:53:05 PM
#398   AMGN 3Q17 CC slides: DewDiligence 10/25/17 04:24:33 PM
#397   https://seekingalpha.com/article/4107923-amgen-allergan-avastin-biosimilar-appro Inoviorulez 09/19/17 06:49:25 PM
#396   https://seekingalpha.com/article/4092782-amgen-looks-enhance-cholesterol-drug Inoviorulez 07/31/17 05:45:49 PM
#395   AMGN 2Q17 CC slides: DewDiligence 07/25/17 04:39:58 PM
#394   https://seekingalpha.com/article/4089618-amgen-novartis-first-mover-advantage-mu Inoviorulez 07/23/17 02:28:01 AM
#393   https://seekingalpha.com/article/4088415-amgen-receives-crl-osteoporosis-drug-ne Inoviorulez 07/18/17 11:43:44 AM
#392   https://seekingalpha.com/article/4087466-amgen-receives-fda-approval-blincyto Inoviorulez 07/13/17 09:18:10 AM
#391   The ins and outs of the Amgen v HONEYDEG 06/13/17 12:25:34 PM
#390   The ins and outs of the Amgen v HONEYDEG 06/13/17 12:25:29 PM
#389   http://news.sky.com/story/ovarian-cancer-drug-hailed-as-biggest-breakthrough-in- sci101 06/03/17 01:48:00 PM
#388   Confidential Treatment Order (ct Order) TREND1 05/30/17 03:55:49 PM
#387   DEW here is exact post TREND1 05/30/17 03:37:38 PM
#386   SEE MNKD BOARD TREND1 05/30/17 03:35:10 PM
#385   First I've heard of that notion. Where did DewDiligence 05/30/17 03:32:35 PM
#384   Dew Do you see AMGN taking over MNKD ? TREND1 05/30/17 03:31:34 PM
#383   FLOAT= 735.16M TREND1 05/30/17 03:24:18 PM
#382   PE = 15.1 TREND1 05/30/17 03:22:41 PM
#381   EPS = 10.32 TREND1 05/30/17 03:21:40 PM
#380   AMGN TREND1 05/30/17 03:17:29 PM
#379   AMGN offers “money-back” pricing on Repatha for US DewDiligence 03/18/17 11:27:10 AM
#378   The Appellate Court stayed the decision pending appeal, DewDiligence 02/12/17 06:04:40 PM
#377   Regeneron Pharmaceuticals And Sanofi Loses On A Suit trendmkr 02/09/17 02:07:28 PM
#376   5yr DCF imply Amgen Inc $AMGN is 20% ValueInvestor15 02/01/17 10:30:31 AM
#375   FDA approves AMGN’s Humira biosimilar: DewDiligence 09/23/16 07:13:48 PM
#374   AMGN---GLTA! Diogenes of Sinope 09/15/16 09:57:54 AM
#373   AMGN JefftDecker 09/07/16 12:09:28 PM
#372   AMGN/AGN report phase-3 data for Herceptin FoB: #msg-124404733. DewDiligence 08/09/16 10:43:03 AM
#371   It's a small risk for AMGN, since the DewDiligence 08/02/16 06:26:03 PM
#370   Any thoughts on the Advaxis deal? gccarlin99 08/02/16 06:21:25 PM
#369   AMGN DAY TREND1 07/28/16 01:09:17 PM
#368   AMGN DAY TREND1 07/25/16 03:08:51 PM
#367   Short % of Float = 1.19% TREND1 07/25/16 02:42:35 PM
#366   Inst % Owned = 88% TREND1 07/25/16 02:26:16 PM
#365   EPS = 9.15 TREND1 07/25/16 02:24:56 PM
#364   AMGN DAY TREND1 07/23/16 12:22:25 PM
#363   AMGN bullish 163.03 stocktrademan 07/21/16 02:13:23 PM
#362   This Bounce Has Serious Legs: $AMGN ITMS 06/28/16 12:11:37 PM
#361   The Big Short's Dr. Michael Burry goes long 0dd Lot 05/23/16 08:42:00 PM
#360   $AMGN Daily and Weekly Charts http://www.stock $Pistol Pete$ 02/18/16 09:28:01 PM
#359   Who Would Make a Good Suitor for Shield nyctraydr 02/15/16 11:57:25 AM
#358   $AMGN Daily Chart http://www.stockcharts.com/c $Pistol Pete$ 02/14/16 05:21:11 PM
PostSubject